Clin Surg | Volume 1, Issue 1 | Research Article | Open Access

1β and TNF-α as a Biomarker of Recurrence in Malignant Eyelid Tumours

Sayeed K1, Kaur A1*, Bhasker SK1 and Pant AB2

1Department of Ophthalmology, King George’s Medical University, India
2Department of Ophthalmology, Indian Institute of Toxicology and Research, India

*Correspondance to: Kaur A 

Fulltext PDF

Abstract

Aim: To establish a correlation between cytokine levels (IL-1β, TNF-α and IL-10) and establishing them as a biomarker of recurrence in malignant eyelid tumours.Method: Prospective observational cross-sectional case-control study of 38 consecutive cases of malignant eyelid tumours that underwent surgical treatment over a period of 18 months. 26 age and sex matched controls with other non-inflammatory, non- neoplastic eyelid disorders. The levels of the cytokines [IL-1β (Interleukin- 1β), TNF-α (tumour necrosis factor-α), IL-10 (Interleukin-10)] (in pg/ml) were determined by using ELISA Kit. Data was analyzed statistically.Result: On comparing the mean cytokine levels of the two groups, t-test revealed significantly higher levels of IL- 1β (16.39 ± 2.86 vs. 14.62 ± 3.72, t=2.17, p=0.034), TNF-α (19.32 ± 3.47 vs. 16.74 ± 4.45, t=2.61, p=0.011) and IL-10 (24.79 ± 5.87 vs. 21.61 ± 4.61, t=2.33, p=0.023) in cases. ANOVA revealed significantly different levels of IL- 1β (F=7.86, p<0.001), TNF-α (F=7.42, p<0.001) and IL- 10 (F=4.36, p=0.006) between tumour and it’s three adjacent tissues.Conclusion: Cytokine levels (IL-1β, TNF-α and IL-10) in the adjacent tissues beyond safety margins were normal and comparable to that in controls suggesting the margins to be tumour free. Highly significant lower levels of IL-1β and TNF-α in tissues beyond safety margins can be used as an important predictor for local recurrence of tumour.

Keywords:

Malignant eyelid tumour; IL-1β, TNF-α; Recurrence

Citation:

Sayeed K, Kaur A, Bhasker SK, Pant AB. IL-1β and TNF-α as a Biomarker of Recurrence in Malignant Eyelid Tumours. Clin Surg. 2016; 1: 1047.

Subscribe to Our Newsletter